A novel method of detecting and destroying viral transmissions such as SARS-CoV-2 transmission is described. The proposed technique uses a light source such as that from a smart phone and a mobile spectrophotometer to enable detection of proteins in solution. The technique allows for detecting soluble preparations of for example spike protein subunits from SARS-CoV-2, followed by detection of the actual binding potential of the spike protein with its host receptor, for example the angiotensin-converting enzyme 2 (ACE2) or other antigens or elements. The results are validated by showing that this method can detect antigen-antibody binding using two independent protein-antibody pairs. Finally, this technique is combined with DC bias to show that introduction of a current in the system can be used to disrupt the antigen-antibody reaction, suggesting that this technique can be a powerful means of disrupting virus transmission by destroying virus-receptor interactions.

A method for evaluating a test article provided by a subject for an attribute, such as a medical, industrial, veterinary, agricultural, food, or other attribute, is provided. The design includes providing a cassette comprising at least one ligand selected to match the attribute, applying the test article provided by the patient to the at least one ligand of the cassette, transmitting light energy toward the test article applied to the at least one ligand, sensing optical attributes of light energy provided from the test article applied to the at least one ligand, and providing sensed attributes of the light energy sensed to an electronic device.

The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.

A laboratory test kit includes a development part 12 for developing thereon a test sample containing a virus, reagent portion 13 and a recognition portion 17. On the recognition portion 17, first and second specific antibodies both derived from a mouse are to be immobilized for specifically recognizing first and second antigen-determining sites respectively both possessed by the virus. The reagent portion 13 includes first and second labeled antibodies both derived from a mouse, which specifically recognize the first and second antigen-determining sites respectively both possessed by the virus and are labeled with a labeling substance. In each of the first and second labeled antibodies, at least one of an antigen site which is recognized by the HAMA or a sugar chain binding site recognized by an antibody which recognizes a sugar chain is defected or modified.

A Covid-19 susceptibility testing device including a receiving chamber configured to receive a human bodily fluid and a reaction medium configured to indicate Covid-19 susceptibility when concentration of an analyte exceeds a predetermined threshold in the human bodily fluid.

Methods are provided herein utilizing a stable cell line capable of efficient infection by African swine fever virus (ASFV) and also provides for the detection of the presence of virus in samples applied to the cells. Detection of the virus by means such as red blood cell rosetting is a surprising result given that the cell line is derived from African green monkeys. This cell line provides a marked improvement over the currently available testing strategies.

This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

A rapid testing mechanism for respiratory viral pathogens includes a filter material positioned to capture exhaled breath particles from a respiratory tract. A portion of the filter material is impregnated with a pathogen binding adsorptive reagent. When the exhaled breath particles pass through the filter material the following occurs: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material; and when pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material.

The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.

The present disclosure may provide a system and method for using a viral respiratory infection detection device, a method comprising: obtaining a biological sample from a subject; preparing the biological sample for testing; placing at least a portion of the prepared biological sample into a sample port of a viral respiratory infection detection device thereby contacting a sample pad with the prepared biological sample thus initiating a first test strip and a second test strip, wherein the first testing strip is formed to detect the binding of a respiratory virus to a recombinant human receptor protein, wherein the second testing strip is formed to detect the binding of a specific respiratory virus to a specific recombinant spike glycoprotein; and analyzing the results of the first test strip and the second test strip.